Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) improve cardiovascular and renal outcomes in patients with type 2 diabetes through distinct mechanisms. However, evidence on clinical outcomes in patients treated with both GLP-1 R...

Descripción completa

Detalles Bibliográficos
Autores principales: Clegg, Lindsay E., Penland, Robert C., Bachina, Srinivas, Boulton, David W., Thuresson, Marcus, Heerspink, Hiddo J. L., Gustavson, Stephanie, Sjöström, C. David, Ruggles, James A., Hernandez, Adrian F., Buse, John B., Mentz, Robert J., Holman, Rury R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805385/
https://www.ncbi.nlm.nih.gov/pubmed/31640705
http://dx.doi.org/10.1186/s12933-019-0942-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805385/
https://www.ncbi.nlm.nih.gov/pubmed/31640705
http://dx.doi.org/10.1186/s12933-019-0942-x

Ejemplares similares